NewAmsterdam Pharma Reports Officer Comp, Director Changes

Ticker: NAMSW · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1936258

Complexity: simple

Sentiment: neutral

Topics: executive-changes, compensation, corporate-governance

TL;DR

**NewAmsterdam Pharma filed an 8-K on Jan 8, 2024, indicating changes in officer compensation and potentially board members, effective Jan 4, 2024.**

AI Summary

NewAmsterdam Pharma Company N.V. filed an 8-K on January 8, 2024, reporting an event that occurred on January 4, 2024. This filing indicates a change in compensatory arrangements for certain officers, as well as potential departures or elections of directors or officers. While specific details are not provided in this excerpt, such changes can signal shifts in leadership strategy or financial incentives, which could impact the company's future direction and, consequently, the stock's performance.

Why It Matters

Changes in executive compensation or board composition can signal strategic shifts or leadership stability, directly influencing investor confidence and the company's long-term outlook.

Risk Assessment

Risk Level: medium — The filing mentions changes in compensatory arrangements and potential director/officer changes without specific details, creating uncertainty about the nature and impact of these events.

Analyst Insight

Investors should monitor future filings from NewAmsterdam Pharma Company N.V. for detailed information regarding the reported changes in officer compensation and board composition, as these specifics will clarify the strategic implications.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by NewAmsterdam Pharma Company N.V.?

The primary purpose of this 8-K filing, dated January 8, 2024, is to report events that occurred on January 4, 2024, specifically concerning 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Regulation FD Disclosure'.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 4, 2024, as stated under 'Date of Report (Date of earliest event reported): January 4, 2024'.

What is the Commission File Number for NewAmsterdam Pharma Company N.V.?

The Commission File Number for NewAmsterdam Pharma Company N.V. is 001-41562, as indicated in the filing.

Where are the principal executive offices of NewAmsterdam Pharma Company N.V. located?

The principal executive offices of NewAmsterdam Pharma Company N.V. are located at Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.

Does this 8-K filing provide specific details about the changes in compensatory arrangements or director/officer movements?

No, this specific excerpt of the 8-K filing only lists the categories of information being reported (e.g., 'Compensatory Arrangements of Certain Officers') but does not provide the detailed specifics of these changes, such as names, dollar amounts, or reasons for departure/election.

Filing Stats: 966 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-01-08 08:21:13

Key Financial Figures

Filing Documents

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 4, 2024, the board of directors (the "Board") of NewAmsterdam Pharma Company N.V. (the "Company") increased the size of the Board to ten and appointed Willian H. Lewis, J.D., M.B.A., as Chair of the Board. Mr. Lewis will serve as a temporary non-executive director until his formal appointment at the Company's next general meeting of shareholders. The Board has determined that Mr. Lewis meets the requirements for independence under the applicable listing standards of the Nasdaq Stock Market LLC and the Securities and Exchange Act of 1934, as amended, and has appointed him to serve on the Audit Committee and Compensation Committee of the Board. Mr. Lewis has served as Chief Executive Officer of Insmed Incorporated, a global commercial-stage biopharmaceutical company, since 2012, and as Chair of Insmed Incorporated's board of directors since 2018. Mr. Lewis succeeds Sander Slootweg, Managing Partner at Forbion, who has served as Chairman of the Board since inception. As consideration for his service on the Board, Mr. Lewis will be eligible to receive an annual cash retainer of $40,000, an additional $30,000 annually for serving as Chair of the Board and an additional $20,000 annually for serving as lead independent director. Mr. Lewis will also be granted options to subscribe for 100,000 of the Company's ordinary shares under the Company's Long-Term Incentive Plan (the "Initial Grant"). The first 25% of the ordinary shares underlying the Initial Grant will vest on the first anniversary of the vesting start date and the remaining shares will vest in equal monthly installments thereafter for three years, subject to his continued service on the Board. Mr. Lewis will also be entitled to receive an annual retainer of $7,500 and $5,000 for serving on the Audit Committee and Compensation Committee, respe

01

Item 7.01 Regulation FD Disclosure. On January 8, 2024, the Company issued a press release announcing Mr. Lewis' appointment to the Board. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On January 8, 2024, the Company posted an updated corporate investor presentation on its website (https://www.newamsterdampharma.com/). A copy of the corporate investor presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information contained on, or that can be accessed from, the Company's website is not incorporated into, and does not constitute a part of, this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.2, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated January 8, 2024 99.2 NewAmsterdam Pharma Company N.V. Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing